Drug intelligence / Profile preview

miR-17~92 targeting RNA aptamer

Development stage
Preclinical
Modality
RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

miR-17~92 targeting RNA aptamer is an RNA aptamer designed to specifically target the primary transcript of the oncogenic microRNA-17~92 (pri-miR-17~92) cluster. This cluster, also known as oncomiR-1, is frequently overexpressed in various human cancers and plays a crucial role in regulating cell proliferation, apoptosis, and differentiation. The aptamer functions by binding to the pri-miR-17~92 transcript, which interferes with its processing and maturation into individual microRNAs such as miR-17, miR-18a, miR-19b, and miR-20a. By inhibiting the biogenesis of these oncogenic microRNAs, the aptamer aims to suppress cancer cell growth, induce cell cycle arrest, and promote apoptosis, thereby offering a therapeutic strategy for cancers driven by the miR-17~92 cluster.

Other names
pri-miRNA-17~92 aptamerpri-apt

Beyond the preview

Go deeper on miR-17~92 targeting RNA aptamer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-17~92 targeting RNA aptamer.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call